Impax Laboratories Inc., of Amsterdam, said the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending that Numient (IPX066), a modified-release oral capsule formulation of levodopa-carbidopa, be granted approval for the symptomatic treatment of adult patients with Parkinson's disease.